Ask about this productRelated genes to: DYNC1I2 antibody
- Gene:
- DYNC1I2 NIH gene
- Name:
- dynein cytoplasmic 1 intermediate chain 2
- Previous symbol:
- DNCI2
- Synonyms:
- DIC74
- Chromosome:
- 2q31.1
- Locus Type:
- gene with protein product
- Date approved:
- 1995-11-15
- Date modifiied:
- 2016-03-02
Related products to: DYNC1I2 antibody
Related articles to: DYNC1I2 antibody
- To explore the mechanism by which alpha-lipoic acid (ALA) regulates mitochondrial axonal transport to protect the sciatic nerve in diabetic rats. - Source: PubMed
Publication date: 2026/04/01
Tian JiaxinAn JingwenSong LinchunZhang WangChen DieZhang TianyaBen Ying - Locally advanced rectal cancer (LARC) exhibits significant heterogeneity in response to neoadjuvant chemotherapy (NAC), with poor responders facing delayed treatment and unnecessary toxicity. Although MRI provides spatial pathophysiological information and proteomics reveals molecular mechanisms, current single-modal approaches cannot integrate these complementary perspectives, resulting in limited predictive accuracy and biological insight. - Source: PubMed
Publication date: 2025/09/01
Li YanDing JiaxuanDu FenqiWang ZhongxingLiu ZeyuanLiu YanlongZhou YangZhang Qiuju - This study aims to clinically and genetically assess 30 unrelated consanguineous Pakistani families from various ethnic backgrounds, all exhibiting features of neurodevelopmental disorders (NDDs). - Source: PubMed
Publication date: 2024/08/30
Paracha Sohail AzizNawaz ShoaibTahir Sarwar MuhammadShaheen AsmatZaman GoharAhmed JawadShah FahimKhwaja SundusJan AbidKhan NidaKamal Mohammad AzharAlam QamreAbbas SafdarFarman SamanWaqas AhmedAlkathiri AfnanHamadi AbdullahSantoni FedericoUllah NaseebKhalid BismaAntonarakis Stylianos EFakhro Khalid AUmair MuhammadAnsar Muhammad - The efficacy of treatments targeting recurrent or metastatic head and neck squamous cell carcinoma are unsatisfactory in practice for patients with a ECOG PS score ≥ 2. Thus, this study retrospectively evaluated the safety and efficacy of a programmed cell death 1 inhibitor (tislelizumab) combined with an epidermal growth factor receptor inhibitor (nimotuzumab) in treating patients with a PS score ≥ 2 who suffer from recurrent or metastatic oral squamous cell carcinoma (OSCC). - Source: PubMed
Publication date: 2024/01/16
Wu Wen-JieAn Pu-GenZhong Yi-WeiHu XiaoWang LinZhang Jie - Lung adenocarcinoma (LUAD) is one of the leading malignant cancers. Aggrephagy plays a critical role in key genetic events for various cancers; yet, how aggrephagy functions within the tumor microenvironment (TME) in LUAD remains to be elucidated. - Source: PubMed
Publication date: 2023/12/13
Sun XintiMeng FeiNong MinyuFang HaoLu ChengluWang YanZhang Peng